Skip to main content
OpenTrials

Clinical trial condition

Recurrent WHO Grade II Glioma

Explore clinical trials studying Recurrent WHO Grade II Glioma. Study availability and eligibility vary by location and protocol.

4 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Recurrent WHO Grade II Glioma trial results

Active, not recruiting

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

NCT03749187

Conditions
Astrocytoma, Glioblastoma, Glioma, +16 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • Yale University New Haven, Connecticut, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
View Trial Details
Completed

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

NCT03914742

Conditions
Astrocytoma, Glioblastoma, Glioma, +12 more
Locations
  • UAB Comprehensive Cancer Center Birmingham, Alabama, United States
  • University of California, Los Angeles Los Angeles, California, United States
  • Yale University New Haven, Connecticut, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States
View Trial Details

Related conditions